We are live on
!
Find out more
Acadia Pharmaceuticals
ACAD
ACAD
142 hedge funds and large institutions have $2.18B invested in Acadia Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 51 increasing their positions, 46 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
1,326% more call options, than puts
Call options by funds: $373M | Put options by funds: $26.2M
300% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 7
46% more capital invested
Capital invested by funds: $1.5B → $2.18B (+$682M)
15% more funds holding
Funds holding: 123 → 142 (+19)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
11% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 46
Holders
142
Holders Change
+19
Holders Change %
+15.45%
% of All Funds
4.6%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.26%
New
28
Increased
51
Reduced
46
Closed
7
Calls
$373M
Puts
$26.2M
Net Calls
+$347M
Net Calls Change
+$154M
Top Buyers
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$43.1M |
| 2 |
Alkeon Capital Management
New York
|
+$35.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$11.9M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.1M |
Top Sellers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$94M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$30.9M |
| 3 |
O
OrbiMed
New York
|
-$20.5M |
| 4 |
DM
Deerfield Management
New York
|
-$19.4M |
| 5 |
VAM
Visium Asset Management
New York
|
-$16.3M |
